Literature DB >> 3132095

Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections.

G Satta1, G Cornaglia, G Foddis, R Pompei.   

Abstract

In pursuit of an in vitro system capable of reliably predicting the activities of antibiotics in serious infections and in infections occurring in immunocompromised hosts, we evaluated the abilities of four drugs to achieve virtually complete killing of bacterial cells growing in human body fluids in amounts which are very high and close to those likely to be present in serious infections; drug concentrations varied with time as they vary in human bronchial secretions or blood or urine (dynamic concentrations). The rationale for such a test was (i) to set up in vitro conditions as close as possible to those the antibiotics encounter in serious infections and (ii) to hold the drugs capable of almost completely killing the bacteria used in the assay to be highly active in vitro and likely to be the most efficacious in the treatment of serious infections. Among the antibiotics used, ceftriaxone proved to be highly active under conditions simulating pulmonary infections and septicemias caused by Streptococcus pneumoniae (bacteria grown in bronchoalveolar fluid or blood; antibiotic concentrations varying with time as in human bronchial secretions or blood) and under conditions simulating blood and urinary infections caused by Escherichia coli (bacteria grown in human blood or urine; antibiotic concentrations varying as in the various fluids). Gentamicin (not tested against pneumococci) appeared to be highly active only under conditions simulating urinary infections caused by E. coli; aztreonam (not tested against pneumococci) and ampicillin (tested only against pneumococci) did not appear to be highly active under any of the test conditions. Only the combination of gentamicin plus either ceftriaxone or aztreonam appeared to be highly active under conditions simulating serious septicemias and urinary infections caused by Psudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132095      PMCID: PMC172219          DOI: 10.1128/AAC.32.4.552

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Activity of imipenem in an in-vitro model simulating pharmacokinetic parameters in human blood.

Authors:  P M Shah
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

2.  The importance of underlying disease in patients with gram-negative bacteremia.

Authors:  M A Freid; K L Vosti
Journal:  Arch Intern Med       Date:  1968-05

3.  In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

Authors:  J Blaser
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

4.  Historical review of in-vitro models.

Authors:  S Grasso
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

5.  Comparative antipseudomonal activity of some newer beta-lactam agents.

Authors:  D Greenwood; A Eley
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

6.  Comparison of skin blisters and implanted cotton threads for the evaluation of antibiotic tissue concentrations.

Authors:  B Hoffstedt; M Walder; A Forsgren
Journal:  Eur J Clin Microbiol       Date:  1982-02       Impact factor: 3.267

7.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; N P Zissis; G Tagari; J Bouzos
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa.

Authors:  R H Eng; S M Smith; C Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

Review 9.  Infections due to gram-negative bacteria: an overview.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec

10.  Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.

Authors:  S A Henry; C B Bendush
Journal:  Am J Med       Date:  1985-02-08       Impact factor: 4.965

View more
  7 in total

1.  Use of Modeling Techniques to Aid in Antibiotic Selection.

Authors:  Alexander A. Firsov; Stephen H. Zinner
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model.

Authors:  A A Firsov; M Ruble; D Gilbert; D Saverino; D Savarino; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

4.  Differences between in vitro and in vivo studies.

Authors:  V Lorian
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; O V Kononenko; S H Zinner; Y A Portnoy
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

6.  Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model.

Authors:  Brianna M Eales; Cole S Hudson; Iordanis Kesisoglou; Weiqun Wang; Michael Nikolaou; Vincent H Tam
Journal:  Antibiotics (Basel)       Date:  2021-10-16

Review 7.  Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches.

Authors:  Wisse van Os; Markus Zeitlinger
Journal:  Antibiotics (Basel)       Date:  2021-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.